References
[1] Benjamin EJ,Muntner P,Alonso A,Bittencourt MS,Callaway CW,et
al.Heart disease and stroke statistics-2019 update: a report from the
American Heart Association[J].Circulation,2019;139:e56-e528.
[2] Zhang S.Atrial fibrillation in mainland China:epidemiology and
current management[J].Heart,2009,95(13):1052-1055.
[3] Chugh SS,Havmoeller R,Narayanan K,Singh D,Rienstra M,et
al.Worldwide epidemiology of atrial fibrillation: a Global Burden of
Disease 2010 Study[J].Circulation,2014;129:837-847.
[4] Colilla S,Crow A,Petkun W,Singer DE,Simon T,Liu X.Estimates of
current and future incidence and prevalence of atrial fibrillation in
the US adult population[J].Am J Cardiol,2013;112:1142-1147.
[5] Krijthe BP,Kunst A,Benjamin EJ,Lip GY,Franco OH,Hofman
A,Witteman JC,Stricker B-H,Heeringa J.Projections on the number of
individuals with atrial fibrillation in the Europ-ean Union, from 2000
to 2060[J].Eur Heart J,2013;34:2746-2751.
[6] Staerk L,Sherer JA,Ko D,Benjamin EJ,Helm RH.Atrial fibrillation:
epidemiology,pathop-hysiology, and clinical outcomes[J].Circ
Res,2017;120:1501-1517.
[7] Chen C, Zhou X, Zhu M, Chen S, Chen J, Cai H, Dai J, Xu X, Mao
W. Catheter ablation versus medical therapy for patients with persistent
atrial fibrillation: a systematic review and meta analysis of evidence
from randomized controlled trials[J]. J Interv Card El-ectrophysiol
2018;52:9-18.
[8] Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, et al.
Effect of catheter ablation vs antiarrhythmic drug therapy on mortality,
stroke, bleeding, and cardiac arrest among patients with atrial
fibrillation:the CABANA randomized clinical trial[J]. JAMA
2019;321:1261-1274.
[9] Noseworthy PA, Gersh BJ, Kent DM, Piccini JP, Packer DL, Shah
ND, Yao X.Atrial fibrillation ablation in practice: assessing CABANA
generalizability[J]. Eur Heart J 2019;40:1257-1264.
[10] Blomström-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM,
Bergfeldt L, Kennebä-ck G, Rubulis A, Malmborg H, Raatikainen P,
Lönnerholm S, Höglund N, Mörtsell D. E-ffect of catheter ablation vs
antiarrhythmic medication on quality of life in patients with atrial
fibrillation: the CAPTAF randomized clinical trial[J].JAMA
2019;321:1059-1068.
[11] January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland
JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA,
Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update
of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With
Atrial Fibrillation: A Report of the American C-ollege of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelin-es and the Heart Rhythm Society in Collaboration With the
Society of Thoracic Surgeons[J]. Circulation,2019;140(2):e125-e151.
[12] Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, et al. 2020
ESC Guidelines for the diagnosis and management of atrial fibrillation
developed in collaboration with the European Association of
Cardio-Thoracic Surgery (EACTS)[J].Eur Heart J,2021;42(5):373-498.
[13] Mujović N, Marinković M, Lenarczyk R, Tilz R, Potpara TS.
Catheter Ablation of Atrial Fibrillation: An Overview for
Clinicians[J]. Advances in Therapy, 2017, 34(62):1897-1917.
[14] Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, et al.
Cryoablation or Drug Therapy for Initial Treatment of Atrial
Fibrillation[J]. N Engl J Med,2021,384(4):305-315.
[15] Kawaji T, Shizuta S, Aizawa T, Yamagami S, Kato M, Yokomatsu T,
Miki S, Ono K, Kimura T. Impact of catheter ablation for atrial
fibrillation on cardiac disorders in patients with coexisting heart
failure[J]. ESC Heart Fail,2021,8(1):670-679.
[16] Xu G, Cai J, Liu Z, Liu E, Jing X, Liu T, Zhang Q, Ye L, Li G.
Clinical efficacy of ”ICE-FIRE” ablation for non-paroxysmal atrial
fibrillation[J]. J Interv Card Electrophys-iol,2021,60(2):205-211.
[17] Sun Y, Xie Y, Du L, Sun J, Liu Z.Inhibition of BRD4 Attenuates
Cardiomyocyte Apoptosis via NF-κB pathway in a Rat Model of Myocardial
Infarction[J].Cardiovascular Therapeutics, 2018:36(2).
[18] Wang Q, Sun Y, Li T, Liu L, Zhao Y, Li L, Zhang L, Meng Y.
Function of BRD4 in the pathogenesis of high glucose‑induced cardiac
hypertrophy[J]. Mol Med Rep. 2019;19(1):499-507.
[19] Song S, Liu L, Yu Y, Zhang R, Li Y, Cao W, Xiao Y, Fang G, Li
Z, Wang X, Wang Q, Zhao X, Chen L, Wang Y, Wang Q. Inhibition of BRD4
attenuates transverse aortic constriction and TGF-β-induced
endothelial-mesenchymal transition and cardiac fibrosis[J]. J Mol
Cell Cardiol. 2019;127:83‐96.
[20] Shuai Song, Wei Cao, Guojian Fang, et al. Brd4 As A Novel
Therapeutic Target For Atrial Fibrosis And Atrial Fibrillation[R].
Heart Rhythm Society Annual Sci-entific Sessions; May 8-11, 2019; San
Francisco.
[21] Yang YM, Shi RH, Xu CX, Li L. BRD4 expression in patients with
essential hypertension and its effect on blood pressure in spontaneously
hypertensive rats. J Am Soc Hypertens. 2018 Dec;12(12):e107-e117.
[22] Cheng C, Liu H, Tan C, Tong D, Zhao Y, Liu X, Si W, Wang L,
Liang L, Li J, et al.(2019) Mutation in NPPA causes atrial fibrillation
by activating inflammation and cardiac fibrosis in a knock-in rat model.
FASEB J 33:8878–8891.
[23] Wu Q, Liu H, Liao J, Zhao N, Tse G, Han B, Chen L, Huang Z, Du
Y. Colchicine prevents atrial fibrillation promotion by inhibiting
IL-1β-induced IL-6 release and atrial fibrosis in the rat sterile
pericarditis model. Biomed Pharmacother. 2020 Sep;129:110384. doi:
10.1016/j.biopha.2020.110384.
[24] Zhang T, Wu Y, Hu Z, Xing W, Kun LV, Wang D, Hu N.
Small-Molecule Integrated Stress Response Inhibitor Reduces
Susceptibility to Postinfarct Atrial Fibrillation in Rats via the
Inhibition of Integrated Stress Responses. J Pharmacol Exp Ther. 2021
Sep;378(3):197-206. doi: 10.1124/jpet.121.000491.
[25] Platonov PG, Mitrofanova LB, Orshanskaya V, Ho SY.Structural
abnormalities in atrial walls are associated with presence and
persistency of atrial fibrillation but not with age[J]. J Am Coll
Cardiol. 2011;58(21):2225‐2232.
[26] Floria M, Radu S, Gosav EM, Cozma D, Mitu O, Ouatu A, Tanase
DM, Scripcariu V, Serban LI. Left Atrial Structural Remodelling in
Non-Valvular Atrial Fibrillation: What Have We Learnt from CMR?
[J].Diagnostics (Basel),2020;10(3):137.
[27] Jeong joo Woo, Dana C Peters, John V Wylie, et al.Correlation
of Left Atrial Voltage Maps with Cardiovascular MR Provides Evidence of
Preexistent Scar in Atrial Fibrillation Patients[J].Circulation,
2008,118:771-776.
[28] Canciello G, de Simone G, Izzo R, Giamundo A, Pacelli F,
Mancusi C, Galderisi M, Trimarco B, Losi MA. Validation of Left Atrial
Volume Estimation by Left Atrial Diameter from the Parasternal Long-Axis
View[J]. J Am Soc Echocardiogr,2017;30(3):262-269.
[29] Bossard M, Knecht S, Aeschbacher S, Buechel RR, Hochgruber T,
Zimmermann AJ, Kessel-Schaefer A, Stephan FP, Völlmin G, Pradella M,
Sticherling C, Osswald S, Kaufma-nn BA, Conen D, Kühne M. Conventional
versus 3-D Echocardiography to Predict Arrhythmia Recurrence After
Atrial Fibrillation Ablation[J]. J Cardiovasc
Electrophysiol,2017;28(6):651-658.
[30] Liao YC, Liao JN, Lo LW, Lin YJ, Chang SL, et al. Left Atrial
Size and Left Ventricular End-Systolic Dimension Predict the Progression
of Paroxysmal Atrial Fibrillation After Catheter Ablation[J]. J
Cardiovasc Electrophysiol,2017;28(1):23-30.
[31] Njoku A, Kannabhiran M, Arora R, Reddy P, Gopinathannair R,
Lakkireddy D, Dom-inic P. Left atrial volume predicts atrial
fibrillation recurrence after radiofrequency ablation: a
meta-analysis[J]. Europace,2018;20(1):33-42.
[32] Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Mohanty S, et
al. Left atrial appendage: an underrecognized trigger site of atrial
fibrillation[J]. Circulation,2010;122(2):109-118.
[33] Kim MN, Lee JJ, Kim SA, Kim YH, Choi JI, Park SM, Park SW, Kim
YH, Shim WJ. The difference of predictors for recurrence after catheter
ablation of non-paroxysmal atrial fibrillation according to follow-up
period[J]. Int Heart J,2014;55(4):312-318.
[34] Shiozawa T, Shimada K, Sekita G, Hayashi H, Tabuchi H, Miura S,
Fujimoto S, Ka-doguchi T, Ouchi S, Aikawa T, Al Shahi H, Takahashi S,
Miyazaki T, Sumiyoshi M, Na-kazato Y, Daida H. Left Atrial Appendage
Volume and Plasma Docosahexaenoic Acid Le-vels Are Associated With
Atrial Fibrillation Recurrence After Catheter Ablation[J]. Cardiol
Res,2017;8(3):96-104.
[35] Pinto Teixeira P, Martins Oliveira M, Ramos R, Rio P, Silva
Cunha P, Delgado AS, Pimenta R, Cruz Ferreira R. Left atrial appendage
volume as a new predictor of atrial fibrillation recurrence after
catheter ablation[J]. J Interv Card
Electrophysiol,2017;49(2):165-171.
[36] Tian X, Zhang XJ, Yuan YF, Li CY, Zhou LX, Gao BL.
Morphological and functionnal parameters of left atrial appendage play a
greater role in atrial fibrillation relapse aft-er radiofrequency
ablation[J]. Sci Rep,2020;10(1):8072.
[37] He Y, Zhang B, Zhu F, Hu Z, Zhong J, Zhu W. Transesophageal
echocardiography measures left atrial appendage volume and function and
predicts recurrence of paroxysmal atrial fibrillation after
radiofrequency catheter ablation[J].
Echocardiography,2018;35(7):985-990.
[38] Polyakova V, Miyagawa S, Szalay Z, Risteli J, Kostin S.Atrial
extracellular matrix remodelling in patients with atrial
fibrillation[J]. J Cell Mol Med,2008;12:189‑208.
[39] Rog-Zielinska EA, Norris RA, Kohl P, Markwald R.The living
scar‑cardiac fibroblasts and the injured heart[J]. Trends Mol Med,
2016;22: 99‑114.
[40] Kohl P and Gourdie RG.Fibroblast‑myocyte electrotonic coupling:
Does it occur in native cardiac tissue?[J]. J Mol Cell Cardiol,
2014;70: 37‑46.
[41] Ongstad E and Kohl P.Fibroblast‑myocyte coupling in the
heart:Potential relevance for therapeutic interventions[J]. J Mol
Cell Cardiol, 2016;91: 238‑246.
[42] Nguyen TP, Qu Z and Weiss JN.Cardiac fibrosis and
arrhythmogenesis: The road to repair is paved with perils[J]. J Mol
Cell Cardiol, 2014;70: 83‑91.
[43] Krul SP, Berger WR, Smit NW, van Amersfoorth SC, Driessen AH,
van Boven WJ, Fiolet JW, van Ginneken AC, van der Wal AC, de Bakker JM,
Coronel R, de Groot JR. Atrial fibrosis and conduction slowing in the
left atrial appendage of patients undergoing thoracoscopic surgical
pulmonary vein isolation for atrial fibrillation[J].Circ Arrhythm
Electrophysiol, 2015;8: 288‑295.
[44] Nattel S. Electrical coupling between cardiomyocytes and
fibroblasts: Experimental testing of a challenging and important
concept[J]. Cardiovasc Res, 2018;114: 349‑352.
[45] Pellman J and Sheikh F.Atrial fibrillation: Mechanisms,
therapeutics, and future directi-ons[J]. Compr
Physiol,2015;5:649‑665.
[46] Siebermair J,Kholmovski EG,Marrouche N.Assessment of left
atrial fibrosis by late gadolinium enhancement magnetic resonance
imaging[J].JACC Clin Electrophysiol,2017; 3: 791-802.
[47] Zghaib T, Keramati A, Chrispin J, Huang D, Balouch MA, Ciuffo
L, Berger RD, M-arine JE, Ashikaga H, Calkins H, Nazarian S, Spragg
DD.Multimodal examination of atrial fibrillation substrate[J].JACC
Clin Electrophysiol,2018; 4: 59-68.
[48] Floria M, Radu S, Gosav EM, Cozma D, Mitu O, Ouatu A, Tanase
DM, Scripcariu V, Serban LI. Left Atrial Structural Remodelling in
Non-Valvular Atrial Fibrillation: What Have We Learnt from CMR?
[J].Diagnostics (Basel),2020;10(3):137.
[49] Chen J, Arentz T, Cochet H, Müller-Edenborn B, Kim S,
Moreno-Weidmann Z, Min-ners J, Kohl P, Lehrmann H, Allgeier J, Trenk D,
Hocini M, Jais P, Haissaguerre M, Jad-idi A. Extent and spatial
distribution of left atrial arrhythmogenic sites, late gadolinium
enhancement at magnetic resonance imaging, and low-voltage areas in
patients with persistent atrial fibrillation: comparison of imaging vs.
electrical parameters of fibrosis and arrhythmogenesis[J].
Europace,2019;21(10):1484-1493.
[50] Qureshi NA, Kim SJ, Cantwell CD, Afonso VX, Bai W, et al.
Voltage during atrial fibrillation is superior to voltage during sinus
rhythm in localizing areas of delayed enhancement on magnetic resonance
imaging: an assessment of the posterior left atrium in patients with
persistent atrial fibrillation[J]. Heart Rhythm,2019;16:1357–1367.
[51] Jeong joo Woo, Dana C Peters, John V Wylie, et al.Correlation
of Left Atrial Voltage Maps with Cardiovascular MR Provides Evidence of
Preexistent Scar in Atrial Fibrillation Patients[J].Circulation,
2008,118:771-776.
[52] Ling LH, McLellan AJ, Taylor AJ, Iles LM, Ellims AH, Kumar S,
Teh A, Lee G, Wong MC, Azzopardi S, Sellenger MA, Morton JB, Kalman JM,
Kistler PM. Magnetic resonance postcontrast T1 mapping in the human
atrium: validation and impact on clinical outcome after catheter
ablation for atrial fibrillation[J]. Heart
Rhythm,2014;11(9):1551-1559.
[53] Lee J, Thornhill RE, Nery P, Robert deKemp, Peña E, Birnie D,
Adler A, Ukwatta E. Left atrial imaging and registration of fibrosis
with conduction voltages using LGE-MRI and electroanatomical
mapping[J]. Computers in Biology and Medicine, 2019, 111:103341.
[54] Yagishita A, Sparano D, Cakulev I, Gimbel JR, Phelan T, Mustafa
H, De Oliveira S, Mackall J, Arruda M. Identification and
electrophysiological characterization of early left atrial structural
remodeling as a predictor for atrial fibrillation recurrence after
pulmonary vein isolation[J]. J Cardiovasc
Electrophysiol,2017;28(6):642-650.
[55] Begg GA, Karim R, Oesterlein T, Graham LN, Hogarth AJ, Page SP,
Pepper CB, Rhode K, Lip GYH, Holden AV, Plein S, Tayebjee MH. Left
atrial voltage, circulating biomarkers of fibrosis, and atrial
fibrillation ablation[J]. PLoS One,2018;13(1):e0189936.
[56] Masuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K,
Kanda T, Tsujimura T, Matsuda Y, Okuno S, Ohashi T, Tsuji A, Mano T.
Left atrial low-voltage areas predict atrial fibrillation recurrence
after catheter ablation in patients with paroxysmal atrial
fibrillation[J]. Int J Cardiol,2018;257:97-101.
[57] Masuda M, Asai M, Iida O, Okamoto S, Ishihara T, Nanto K, Kanda
T, Tsujimura T, Matsuda Y, Okuno S, Hata Y, Mano T. Additional
Low-Voltage-Area Ablation in Patients With Paroxysmal Atrial
Fibrillation: Results of the Randomized Controlled VOLCANO
T-rial[J]. J Am Heart Assoc,2020;9(13):e015927.
[58] Morikawa M, Derynck R, Miyazono K. TGF-β and the TGF-β Family:
Context-Dependent Roles in Cell and Tissue Physiology[J]. Cold
Spring Harb Perspect Biol. 2016;8(5):a021873.
[59] Wang Y, Cai H, Li H, Gao Z, Song K. Atrial overexpression of
microRNA-27b atenuates angiotensin II-induced atrial fibrosis and
fibrillation by targeting ALK5[J]. Hum Cell. 2018;31(3):251-260.
[60] Guo J, Jia F, Jiang Y, Li Q, Yang Y, Xiao M, Xiao H. Potential
role of MG53 in the regulation of transforming-growth-factor-β1-induced
atrial fibrosis and vulnerability to atrial fibrillation[J]. Exp
Cell Res. 2018;362(2):436-443.
[61] Shen H, Wang J, Min J, Xi W, Gao Y, Yin L, Yu Y, Liu K, Xiao J,
Zhang YF, Wang ZN. Activation of TGF-β1/α-SMA/Col I Profibrotic Pathway
in Fibroblasts by Galectin-3 Contributes to Atrial Fibrosis in
Experimental Models and Patients[J]. Cell Physiol Biochem.
2018;47(2):851-863.
[62] Cao F, Li Z, Ding WM, Yan L, Zhao QY. LncRNA PVT1 regulates
atrial fibrosis via miR-128-3p-SP1-TGF-β1-Smad axis in atrial
fibrillation[J]. Molecular Medicine, 2019, 25(1):7.
[63] Mumby S, Gambaryan N, Meng C, Perros F, Humbert M,Wort
SJ,Adcock IM.Bromo-domain and extra-terminal protein mimic JQ1 decreases
inflammation in human vascular endothelial cells: Implications for
pulmonary arterial hypertension[J].Respirology,2017;22:157-164.
[64] Mio C, Conzatti K, Baldan F, Allegri L, Sponziello M,Rosignolo
F, Russo D, Filetti S,Damante G.BET bromodomain inhibitor JQ1 modulates
microRNA expression in thyroid cancer cells[J].Oncol
Rep,2018;39:582-588.